Report: Drug Makers’ Spending In 2023 Failed To Prioritize R&D

By Gabrielle Wanneh / July 5, 2024 at 11:00 AM
As the drug industry and its supporters continue to push back against further implementation of government price controls, saying the controls will hinder investment in future treatments and cures, a report from a nonpartisan special interest watchdog group found the industry spends more on stock buybacks, marketing and other priorities than research and development. Accountable.US Executive Director Tony Carrk wrote last month in a Pittsburgh Post-Gazette op-ed that drug companies could shift their priorities to avoid having to make...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.